Display options
Cite
Song Z. Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. J Thorac Dis. 2014;6(12):1808-12doi: 10.3978/j.issn.2072-1439.2014.11.18.
Song, Z. (2014). Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. Journal of thoracic disease, 6(12), 1808-12. https://doi.org/10.3978/j.issn.2072-1439.2014.11.18
Song, Zhengbo. "Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma." Journal of thoracic disease vol. 6,12 (2014): 1808-12. doi: https://doi.org/10.3978/j.issn.2072-1439.2014.11.18
Song Z. Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma. J Thorac Dis. 2014 Dec;6(12):1808-12. doi: 10.3978/j.issn.2072-1439.2014.11.18. PMID: 25589977; PMCID: PMC4283302.
Copy Download .nbib Format: NLM
Share it on

J Thorac Dis. 2014 Dec;6(12):1808-12. doi: 10.3978/j.issn.2072-1439.2014.11.18.

Chemotherapy with paclitaxel plus carboplatin for relapsed advanced thymic carcinoma.

Journal of thoracic disease

Zhengbo Song

Affiliations

  1. 1 Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China ; 2 Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou 310022, China.

PMID: 25589977 PMCID: PMC4283302 DOI: 10.3978/j.issn.2072-1439.2014.11.18

Abstract

OBJECTIVE: For rarity of thymic carcinoma, no definitive chemotherapeutic regimen has been established in second- or further-line settings. The aim of this study was to evaluate the feasibility and safety of paclitaxel plus carboplatin in advanced thymic carcinoma as second- or further-line treatment in our institute.

METHODS: We evaluated the efficacy and toxicity of paclitaxel plus carboplatin as salvage therapy in 12 patients with previously treated advanced thymic carcinoma from 2005 to 2012 in Zhejiang Cancer Hospital. Survival analysis was evaluated by Kaplan-Meier method.

RESULTS: Twelve patients were included in current study. Four patients achieved stable disease (SD), and three achieved partial response (PR), representing a response rate of 25.0% and disease control rate (DCR) of 58.3%. Median progression-free survival (PFS) and overall survival (OS) were 3.5 and 24.0 months, respectively. The toxicities associated with the paclitaxel plus carboplatin was generally acceptable.

CONCLUSIONS: Paclitaxel plus carboplatin appears to have some activity against thymic carcinoma as second-line or later chemotherapy in advanced thymic carcinoma.

Keywords: Thymic carcinoma; efficacy; paclitaxel; salvage chemotherapy

References

  1. J Clin Oncol. 2011 May 20;29(15):2060-5 - PubMed
  2. Cancer. 2001 Jun 1;91(11):2010-5 - PubMed
  3. Ann Oncol. 2010 Jun;21(6):1168-72 - PubMed
  4. Anticancer Res. 2006 Nov-Dec;26(6C):4851-5 - PubMed
  5. Chemotherapy. 2004 Dec;50(6):279-82 - PubMed
  6. N Engl J Med. 2002 Jan 10;346(2):92-8 - PubMed
  7. Anticancer Res. 2011 Jan;31(1):299-301 - PubMed
  8. Lung Cancer. 2010 Feb;67(2):194-7 - PubMed
  9. Lung Cancer. 2010 Dec;70(3):357-63 - PubMed
  10. Tumori. 2013 Jul-Aug;99(4):e172-6 - PubMed
  11. Curr Treat Options Oncol. 2012 Dec;13(4):527-34 - PubMed
  12. Anticancer Res. 2007 Jul-Aug;27(4C):3005-8 - PubMed
  13. Br J Cancer. 2009 Nov 3;101(9):1549-54 - PubMed
  14. Lung Cancer. 2011 Apr;72(1):68-72 - PubMed
  15. Cochrane Database Syst Rev. 2013 Aug 23;(8):CD008588 - PubMed
  16. Med Oncol. 2010 Jun;27(2):392-6 - PubMed

Publication Types